Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2
- PMID: 15375540
Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2
Abstract
Mutations of p53 tumor suppressor gene increase with tumor progression in colorectal cancers. In this study, we examined the expressions of p33ING1, p14ARF, MDM2 and p21WAF1 mRNA in 25 advanced colorectal cancers by quantitative RT-PCR method, and compared the expression levels of p33ING1, p14ARF, p21WAF1 and MDM2 in relation to p53 status in the tumors. Fifteen of 25 colorectal cancers (60%) showed abnormal accumulation of p53 protein in the nucleus, and the remaining 10 colorectal cancers (40%) were negative for p53 immunostaining. We found a G --> T transition (nonsense mutation) at the first nucleotide of codon 298 (exon 8) in one p53-negative case, and a frame shift mutation on exon 7 in another p53-negative case. In remaining eight p53-negative cases, there was no mutation in the entire open reading frame of p53 cDNA. Interestingly, in eight cases with p53 wild-type gene, 6 cases (75%) showed a marked down-regulation of p14ARF mRNA, and three cases (37.5%) over-expressed MDM2 mRNA. Only one case with wild-type p53 gene showed normal level expression of p53 regulatory-factors (p33ING1, p14ARF, and MDM2). Thus, p53 tumor suppressor pathway was disrupted in 24 of 25 colorectal cancers (96%).
Similar articles
-
RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections: analysis of p53 pathway.Anticancer Res. 2003 May-Jun;23(3C):2891-6. Anticancer Res. 2003. PMID: 12926130
-
Dysfunction of the p53 tumor suppressor pathway in head and neck cancer.Int J Oncol. 2002 Jul;21(1):119-26. Int J Oncol. 2002. PMID: 12063558
-
Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.J Clin Oncol. 2005 Jan 1;23(1):154-64. doi: 10.1200/JCO.2005.03.139. J Clin Oncol. 2005. PMID: 15625370
-
[Messenger RNA expression of p21WAF1/CIP1 in colorectal carcinoma tissues].Nihon Geka Gakkai Zasshi. 1998 Jul;99(7):457-62. Nihon Geka Gakkai Zasshi. 1998. PMID: 9742528 Review. Japanese.
-
Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.Exp Mol Pathol. 2006 Oct;81(2):115-22. doi: 10.1016/j.yexmp.2006.07.001. Epub 2006 Aug 17. Exp Mol Pathol. 2006. PMID: 16919268 Review.
Cited by
-
Is Autophagy Always a Barrier to Cisplatin Therapy?Biomolecules. 2022 Mar 17;12(3):463. doi: 10.3390/biom12030463. Biomolecules. 2022. PMID: 35327655 Free PMC article. Review.
-
Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway.J Biol Chem. 2008 Mar 28;283(13):8624-33. doi: 10.1074/jbc.M707860200. Epub 2008 Jan 23. J Biol Chem. 2008. PMID: 18218619 Free PMC article.
-
Mouse models for the study of colon carcinogenesis.Carcinogenesis. 2009 Feb;30(2):183-96. doi: 10.1093/carcin/bgn267. Epub 2008 Nov 26. Carcinogenesis. 2009. PMID: 19037092 Free PMC article. Review.
-
The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications.Sci Rep. 2022 Dec 15;12(1):21695. doi: 10.1038/s41598-022-25744-8. Sci Rep. 2022. PMID: 36522371 Free PMC article.
-
Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells.Oncotarget. 2014 Feb 15;5(3):841-52. doi: 10.18632/oncotarget.1780. Oncotarget. 2014. PMID: 24553354 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous